Novartis's Ianalumab Meets Goals in Phase 3 Trials to Treat Primary Immune Thrombocytopenia

 

• Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2

• Patients treated with ianalumab also experienced a significantly higher rate of sustained improvements in platelet count, the key secondary endpoint of the study1

https://www.manilatimes.net/2025/08/12/tmt-newswire/globenewswire/novartis-ianalumab-phase-iii-trial-meets-primary-endpoint-in-itp-demonstrating-statistically-significant-improvement-in-time-to-treatment-failure/2166192